Incyte INCY has put up a good performance in the past three months. Shares of the company have gained 9.2% against the industry’s decline of 1.3%. The stock has also outperformed the sector in the ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

As practicing oncologists, we can get bogged down in our individual practices and thus have trouble seeing the bigger picture ...

Panelists discuss how to approach a 67-year-old man with advanced polycythemia vera who is resistant to hydroxyurea, ...

June brought major blood cancer updates, and CURE is sharing the latest in myelofibrosis treatment and FDA breakthroughs, as ...

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS ...

Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry ...

Protagonist Therapeutics Inc. (NASDAQ:PTGX) is one of the best mid cap growth stocks to invest in now. Just as June began, ...

People will frown at you; they will mock you and will often tell you go to bed earlier and not sleep on the job.

The 7MM Polycythemia Vera market size reached approximately USD 2 billion in 2024 and is projected to grow significantly through 2034. Key players such as Incyte, PharmaEssentia, Protagonist ...

Red blood cells (RBCs) play a central role in keeping your body energized and functioning. They carry oxygen from your lungs ...